FDA Brief

Warning letters Drugs

FDA warning letter to

Rechon Life Science AB

High riskIssued Apr 30, 2025Posted Jun 3, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Swedish sterile drugmaker Rechon Life Science over aseptic technique, weak investigations, cleaning and facility problems.

What happened

FDA inspected Rechon Life Science AB's drug manufacturing facility in Limhamn, Sweden, from August 26 to September 6, 2024. Investigators saw an operator touch a critical sterile surface of the ampoule filling line with a gloved hand, found the company's own procedure allowed this, and saw the same contact in a smoke study video. FDA also found weak investigations into rising microbe counts and into failed (out-of-specification) test results, an unvalidated decontamination process, sticky residue on cleanroom walls and floors, and peeling paint and rust in a room leading into an aseptic filling line.

What FDA found

  1. Operators touched critical sterile parts of the filling line with gloved hands, and the company's written procedure said they could.

    21 CFR 211.113(b)
  2. Investigations into repeated microbe finds in cleanrooms and on operators' gowning did not look at all possible sources and blamed talking and staff illness.

    21 CFR 211.192
  3. Failed test results were thrown out as lab error without solid scientific proof and without checking whether manufacturing caused the failure.

    21 CFR 211.192
  4. The decontamination process used on aseptic filling lines was not validated, and biological indicators used to test it came back positive.

    21 CFR 211.42(c)(10)(v)
  5. Walls and floors in several cleanrooms were sticky and left visible residue when wiped, and fibers stuck to the walls.

    21 CFR 211.42(c)(10)(v)
  6. A cleanroom that leads into an aseptic filling line had peeling paint on the ceiling and bubbled paint and rust at the bottom of the door.

    21 CFR 211.58

What FDA wants

FDA tells the company to correct the violations promptly and to reply in writing with details of what it has done and how it will prevent recurrence. The reply should include independent risk assessments of contamination hazards, a review of invalidated out-of-specification results for U.S. products, and cleaning and facility remediation plans.

Who should pay attention

  • companies that buy sterile injectable or ampoule products from this contract manufacturer
  • marketers of U.S. drugs that list this site as a manufacturer
  • quality teams running aseptic filling and cleanroom programs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  4. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk